NUAK1 (NUAK family kinase 1), also known as ARK5 (AMPK-related protein kinase 5), is a serine/threonine kinase belonging to the AMP-activated protein kinase (AMPK) family. It plays a critical role in cellular stress responses, energy homeostasis, and cell proliferation by regulating pathways such as the LKB1-AMPK signaling axis, mTOR, and Hippo. NUAK1 is involved in diverse physiological processes, including cytoskeletal organization, apoptosis, and autophagy, and has been implicated in cancer progression, particularly in tumor metastasis and chemoresistance. Its expression is often upregulated in cancers like breast, colon, and glioblastoma, correlating with poor prognosis.
NUAK1 antibodies are essential tools for studying its expression, localization, and functional interactions in both normal and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP) to investigate NUAK1's role in signaling networks. Researchers also employ them to explore NUAK1's regulatory mechanisms, including phosphorylation events (e.g., at Thr211) and its interplay with binding partners like MYPT1 or PP1β. Commercial NUAK1 antibodies are typically validated for specificity across human, mouse, and rat samples, with monoclonal and polyclonal variants available. Their applications extend to drug discovery, particularly in targeting NUAK1 for anticancer therapies, and in elucidating its contributions to metabolic disorders or neurodegenerative diseases.